Web11 apr. 2024 · Moderate-intensity statin with ezetimibe combination therapy showed similar cardiovascular benefits to those of high-intensity statin monotherapy with ... Web9 aug. 2024 · The patients were classified as statin users (n = 9893, 85.2%) and statin non-users (n = 1719, 14.8%). Thereafter, statin users were further divided into high-intensity (n = 2984, 30.2%) and low-moderate-intensity statin users (n = 6909, 69.8%).
Long-term efficacy and safety of moderate-intensity statin with ...
WebTable 3. Outcomes for Patients Receiving High- vs Moderate-Intensity Statins by Age Group a. View ... lovastatin, 20 mg, simvastatin, 10 mg, pitavastatin, 1 mg, and … WebTable 2 Phase III trials on the PCSK9 inhibitors, ... Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870–1882. 91. arsen hotel dalyan
Shawn Olson, MD, MPH, DipABLM, FACOEM en LinkedIn: Prolonged Moderate …
WebTable 1 Pharmacokinetic characteristics of statins 8,13 Note: With kind permission from Springer Science+Business Media: Advances in therapy, ... Current guidelines recommend its use when moderate-intensity statin therapy is indicated. 6 A drawback to its use is likely to be its cost. Web11 apr. 2024 · Generally, of the study participants, only 20% reported taking high-strength statins, and 60% were on moderate-intensity statin therapy. These results are in line with findings from research showing that only 21% of U.S. adult patients took high-intensity statins in the 2008-2009 period and 30% in the 2012-2013 cycle (Salami et al. 2024). Web30 jun. 2024 · The type and dose chosen should achieve LDL-C values of <55mg/dL (<1.4 mmol/L) AND a reduction of at least 50%. This includes atorvastatin 40-80mg and rosuvastatin 20-40mg (see Table 1) [2]. LDL-C levels should be re-checked after 6-8 weeks. arsenia meaning